Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EVONIK INDUSTRIES AG

(EVK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evonik Industries : Virtual CEO Conference, Paris (Exane)

06/10/2021 | 02:50am EDT

Evonik

Leading Beyond Chemistry

Company Presentation Q1 2021

Key Messages Q1 2021

Strong start into the year driven by "specialty growth"

Specialty growth

  • Higher sales and adj. EBITDA in all three growth divisions - both vs. Q1 2020 and the pre- pandemic levels in Q1 20219
  • Specialty Additives with further margin expansion on the back of strong demand across the division
  • Nutrition & Care with clear margin improvement driven by shift to system solutions, active cost management and increasing prices
  • Smart Materials recording strong volume growth supported by ongoing macro-economic recovery

Strong start into the year

  • Adj. EBITDA up 15% yoy at €588 m
  • Record-highfree cash flow for a first quarter
    (€312 m)

Outlook range narrowed upwards

  • Adj. EBITDA expected between €2.1 and 2.3 bn (previously: between €2.0 and 2.3 bn)
  • Driven by upgraded divisional outlook for Specialty Additives and Nutrition & Care
  • Targeting growth above 2019 pre-pandemic level

2 | May / June 2021 | Evonik Q1 2021 Company Presentation

Table of contents

  1. Evonik at a glance
  2. Strategy
  3. Financials Q1 2021
  4. Appendix

3 | May / June 2021 | Evonik Q1 2021 Company Presentation

LEADING BEYOND CHEMISTRY

TO IMPROVE LIFE, TODAY AND TOMORROW

4 | May / June 2021 | Evonik Q1 2021 Company Presentation

Leading Beyond Chemistry - Our purpose

Evonik on the way to become a best-in-class specialty chemicals company

Leading …

… Beyond …

… Chemistry

  • Leading market positions in 80% of our business
  • Leading key financial indicators
  • Connecting skills and perspectives
  • Develop solutions together with partners
  • Sustainability key driver of growth
  • Clear focus on specialty chemicals
  • Target 100% specialty portfolio

5 | May / June 2021 | Evonik Q1 2021 Company Presentation

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Evonik Industries AG published this content on 10 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 June 2021 06:49:01 UTC.


ę Publicnow 2021
All news about EVONIK INDUSTRIES AG
08/02EVONIK INDUSTRIES : acquires German biotech company JeNaCell to expand biomateri..
PU
07/26EVONIK INDUSTRIES AG : Preliminary announcement of the publication of financial ..
EQ
07/26DGAP-AFR : Evonik Industries AG: Preliminary announcement of the publication of ..
DJ
07/23EVONIK INDUSTRIES : presents its latest 'Living polyurethanes' solutions for imp..
AQ
07/22EVONIK INDUSTRIES : presents its latest “Living polyurethanes” solut..
PU
07/15EVONIK : Sell rating from Baader Bank
MD
07/14EVONIK INDUSTRIES : new emissions testing facility enables more sustainable poly..
PU
07/13EVONIK : Warburg Research reaffirms its Neutral rating
MD
07/12THE ROAD TO GREATER ENERGY EFFICIENC : MACBETH project reaches important milesto..
PU
07/09EVONIK - MILESTONE IN MARL : Minister President Armin Laschet inaugurates world'..
AQ
More news
Financials
Sales 2021 13 366 M 15 851 M 15 851 M
Net income 2021 761 M 903 M 903 M
Net Debt 2021 2 621 M 3 108 M 3 108 M
P/E ratio 2021 18,2x
Yield 2021 3,93%
Capitalization 13 775 M 16 331 M 16 336 M
EV / Sales 2021 1,23x
EV / Sales 2022 1,17x
Nbr of Employees 32 745
Free-Float 41,1%
Chart EVONIK INDUSTRIES AG
Duration : Period :
Evonik Industries AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVONIK INDUSTRIES AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 29,56 €
Average target price 31,35 €
Spread / Average Target 6,05%
EPS Revisions
Managers and Directors
Christian Kullmann Chairman-Executive Board
Ute Wolf Chief Financial Officer
Bernd T÷njes Chairman-Supervisory Board
Andreas Fischer Chief Innovation Officer
Siegfried Luther Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVONIK INDUSTRIES AG10.79%16 371
BASF SE2.10%72 133
SHIN-ETSU CHEMICAL CO., LTD.1.08%69 646
DUPONT DE NEMOURS, INC.4.98%39 724
ROYAL DSM N.V.21.13%34 618
ASAHI KASEI CORPORATION15.60%15 556